Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and CIN3+, which supports an extension of the cervical screening interval beyond five years for some, according to a study.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
Oncologists should raise awareness of HPV-related cancers and role of vaccinations
Anal cancer is associated with human papillomavirus (HPV) infection, and some women are at increased likelihood of have both diseases.
Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.
Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.
HPV subtypes 5, 8, 17, 20, and 38 have been associated with a significant increased cancer risk.
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
One dose of the HPV vaccine may be sufficient to protect girls from cervical cancer rather than the currently recommended three doses.
Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Men benefit indirectly but not from cancer risk associated with the virus.
Human papillomavirus (HPV) vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
Improved survival and treatment response was seen in HPV-16 positive patients.
A prospective study found that patients with human papillomavirus-related disease had better treatment response than HPV-negative patients.
Investigators have uncovered genomic differences, with potentially important clinical implications, in head and neck cancers caused by infection with the human papillomavirus.
Researchers note that CDC recommends vaccination at age 11 or 12, but only half of girls receiving the vaccination get it at the proper age.
ACOG still recommending women aged 30 to 65 be screened with Pap or HPV/Pap combination, however.
The FDA has approved Gardasil 9 for the prevention of anal, cervical, vaginal, and vulvar cancers.
Number of adolescent girls receiving the human papillomavirus (HPV) vaccine much lower in states with higher rates of cervical cancer.
A clinical trial is underway that may provide women with a more accurate way to detect cervical cancer.
A long-term follow-up study shows the sustained efficacy, immunogenicity, and safety of GlaxoSmithKline's human papillomavirus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than 9 years, and vaccine efficacy (VE) against incident infection was 100%.
Physicians have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the HPV shed from cancer cells lingering in the mouth or other parts of the body.
Registry data show increase in incidence rates of HPV-related oropharyngeal and anal cancers are up in Canada.
Human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study.
Infection with human papillomavirus is known to induce cancer. Many of the mutations that cause this virally induced cancer occur in a family of genes that normally combats viral infections, according to new research.
The new human papillomavirus (HPV) test has higher sensitivity and specificity than Pap testing for cervical cancer, according to an ideas and opinion piece published online.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|